Related Experiment Video
Updated: Jun 2, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Single-agent gemcitabine in elderly patients with unresectable biliary tract cancer
Hitoshi Kuriyama1, Kenichi Kawana, Reo Taniguchi
1Division of Gastroenterology, Chigasaki Municipal Hospital, 5-15-1 Honson, Chigasaki-city, Kanagawa 253-0042, Japan.
Background/Aims:
This study examines the effect of systemic chemotherapy with gemcitabine (GEM) on survival in elderly patients (aged > or =70 years) with unresectable biliary tract cancer and compares it with best supportive care (BSC).
Methodology:
We conducted a retrospective study of consecutive patients aged > or =70 years, with unresectable biliary tract cancer who were administered GEM (800-1000 mg/m2) on days 1, 8, and 15 every 4 weeks as a first-line treatment.
Results:
Twenty-eight patients were enrolled: 13 (46.4%) received chemotherapy with GEM and 15 (53.6%) received BSC. No cases of complete or partial response were observed. Stable disease was observed in 9 patients (69.2%) and progressive disease in 2 patients (15.4%). Disease control rate was 69.2%. The median overall survival time of patients treated with GEM and BSC was 9.1 and 2.9 months, and the 1-year survival rates were 15.4% and 6.7% respectively. Grade 3/4 neutropenia occurred in three patients (23.1%), leukopenia in two patients (15.4%) and anemia in one patient (7.7%). Grade 3 non-hematologic toxicities were constipation (7.7%) and fatigue (7.7%).
Conclusions:
Chemotherapy with single-agent GEM is a safe and well tolerated regimen for elderly patients with unresectable biliary tract cancer.
Related Concept Videos
Treatment Resistent Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers